ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

Related news

ADMAADMA Biologics2026-02-25 21:05 EST

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-03-09 20:15 EST

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

MDXGMiMedx2026-02-25 21:01 EST

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

STTKShattuck Labs2026-06-09 12:00 EST

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

STTKShattuck Labs2025-05-01 20:20 EST

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

View all latest news

ADMA Biologics

Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for...